vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($221.4M vs $185.2M, roughly 1.2× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs 0.2%, a 0.7% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 6.7%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 11.7%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
FOLD vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $221.4M |
| Net Profit | $1.7M | $433.0K |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | 0.2% |
| Net Margin | 0.9% | 0.2% |
| Revenue YoY | 23.7% | 6.7% |
| Net Profit YoY | -88.5% | -60.5% |
| EPS (diluted) | $0.00 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $221.4M | ||
| Q4 25 | $185.2M | $220.8M | ||
| Q3 25 | $169.1M | $222.4M | ||
| Q2 25 | $154.7M | $204.3M | ||
| Q1 25 | $125.2M | $207.4M | ||
| Q4 24 | $149.7M | $201.4M | ||
| Q3 24 | $141.5M | $196.4M | ||
| Q2 24 | $126.7M | $177.5M |
| Q1 26 | — | $433.0K | ||
| Q4 25 | $1.7M | $12.8M | ||
| Q3 25 | $17.3M | $18.8M | ||
| Q2 25 | $-24.4M | $10.7M | ||
| Q1 25 | $-21.7M | $11.4M | ||
| Q4 24 | $14.7M | $22.2M | ||
| Q3 24 | $-6.7M | $18.8M | ||
| Q2 24 | $-15.7M | $5.0M |
| Q1 26 | — | — | ||
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 8.6% | 7.1% | ||
| Q3 25 | 20.3% | 11.2% | ||
| Q2 25 | -6.1% | 6.9% | ||
| Q1 25 | -6.3% | 8.1% | ||
| Q4 24 | 10.7% | 13.6% | ||
| Q3 24 | 15.3% | 13.3% | ||
| Q2 24 | 11.8% | 4.2% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | 0.9% | 5.8% | ||
| Q3 25 | 10.2% | 8.4% | ||
| Q2 25 | -15.8% | 5.2% | ||
| Q1 25 | -17.3% | 5.5% | ||
| Q4 24 | 9.8% | 11.0% | ||
| Q3 24 | -4.8% | 9.6% | ||
| Q2 24 | -12.4% | 2.8% |
| Q1 26 | — | $0.01 | ||
| Q4 25 | $0.00 | $0.23 | ||
| Q3 25 | $0.06 | $0.33 | ||
| Q2 25 | $-0.08 | $0.19 | ||
| Q1 25 | $-0.07 | $0.21 | ||
| Q4 24 | $0.05 | $0.40 | ||
| Q3 24 | $-0.02 | $0.35 | ||
| Q2 24 | $-0.05 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $162.0M |
| Total DebtLower is stronger | $392.7M | $127.8M |
| Stockholders' EquityBook value | $274.2M | $339.9M |
| Total Assets | $949.9M | $852.2M |
| Debt / EquityLower = less leverage | 1.43× | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $162.0M | ||
| Q4 25 | $293.5M | $162.8M | ||
| Q3 25 | $263.8M | $169.1M | ||
| Q2 25 | $231.0M | $70.7M | ||
| Q1 25 | $250.6M | $96.0M | ||
| Q4 24 | $249.9M | $172.0M | ||
| Q3 24 | $249.8M | $161.9M | ||
| Q2 24 | $260.1M | $115.5M |
| Q1 26 | — | $127.8M | ||
| Q4 25 | $392.7M | $101.4M | ||
| Q3 25 | $392.0M | $87.1M | ||
| Q2 25 | $391.3M | $73.8M | ||
| Q1 25 | $390.7M | $94.4M | ||
| Q4 24 | $390.1M | $120.1M | ||
| Q3 24 | $389.5M | $125.7M | ||
| Q2 24 | $388.9M | $137.3M |
| Q1 26 | — | $339.9M | ||
| Q4 25 | $274.2M | $335.9M | ||
| Q3 25 | $230.4M | $328.1M | ||
| Q2 25 | $204.3M | $306.8M | ||
| Q1 25 | $193.6M | $293.9M | ||
| Q4 24 | $194.0M | $280.0M | ||
| Q3 24 | $178.8M | $260.2M | ||
| Q2 24 | $132.5M | $239.4M |
| Q1 26 | — | $852.2M | ||
| Q4 25 | $949.9M | $834.0M | ||
| Q3 25 | $868.8M | $826.1M | ||
| Q2 25 | $815.3M | $740.8M | ||
| Q1 25 | $789.8M | $720.4M | ||
| Q4 24 | $785.0M | $753.8M | ||
| Q3 24 | $786.6M | $744.6M | ||
| Q2 24 | $749.5M | $706.0M |
| Q1 26 | — | 0.38× | ||
| Q4 25 | 1.43× | 0.30× | ||
| Q3 25 | 1.70× | 0.27× | ||
| Q2 25 | 1.92× | 0.24× | ||
| Q1 25 | 2.02× | 0.32× | ||
| Q4 24 | 2.01× | 0.43× | ||
| Q3 24 | 2.18× | 0.48× | ||
| Q2 24 | 2.93× | 0.57× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $7.1M |
| Free Cash FlowOCF − Capex | $16.0M | — |
| FCF MarginFCF / Revenue | 8.6% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 9.62× | 16.33× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $7.1M | ||
| Q4 25 | $16.3M | $3.1M | ||
| Q3 25 | $35.7M | $57.1M | ||
| Q2 25 | $-26.5M | $18.1M | ||
| Q1 25 | $7.8M | $-789.0K | ||
| Q4 24 | $-3.9M | $23.0M | ||
| Q3 24 | $-23.0M | $67.5M | ||
| Q2 24 | $22.7M | $10.0M |
| Q1 26 | — | — | ||
| Q4 25 | $16.0M | $-19.2M | ||
| Q3 25 | $35.3M | $40.6M | ||
| Q2 25 | $-28.9M | $6.8M | ||
| Q1 25 | $7.5M | $-11.7M | ||
| Q4 24 | $-4.2M | $19.6M | ||
| Q3 24 | $-23.3M | $60.0M | ||
| Q2 24 | $21.6M | $3.0M |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | -8.7% | ||
| Q3 25 | 20.9% | 18.3% | ||
| Q2 25 | -18.7% | 3.4% | ||
| Q1 25 | 6.0% | -5.7% | ||
| Q4 24 | -2.8% | 9.7% | ||
| Q3 24 | -16.5% | 30.6% | ||
| Q2 24 | 17.0% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 10.1% | ||
| Q3 25 | 0.2% | 7.4% | ||
| Q2 25 | 1.6% | 5.5% | ||
| Q1 25 | 0.2% | 5.3% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 0.3% | 3.8% | ||
| Q2 24 | 0.9% | 4.0% |
| Q1 26 | — | 16.33× | ||
| Q4 25 | 9.62× | 0.24× | ||
| Q3 25 | 2.06× | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | -0.27× | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
UTI
Segment breakdown not available.
